InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has begun development of a novel formulation as a targeted prophylactic treatment. The company is developing the drug formulation in accordance with its sponsored research agreement with Columbia University. Designated as SPC-15, the treatment will be designed for stress, anxiety and PTSD. Stress-related disorders such as these are becoming…